Authors
Noora Hannuksela, Outi Kuittinen, Aino Rönkä, Anna Anttalainen, Liisa Ukkola-Vuoti, Iiro Toppila, Johanna Vikkula, Jan Seppälä, Kristiina Vuolukka, Katja Marin, Hanne Kuitunen, Tatu Miettinen, Anu Partanen
Published in
Annals of hematology. Volume 105. Issue 11. Jul 22, 2026. Epub Jul 22, 2026.
Abstract
Hodgkin lymphoma (HL) is a B-cell neoplasm with a cure rate of 90%. Previous data on late morbidity in patients with HL cover the era of older treatment modalities. This real-world study consisted of 2912 patients diagnosed with HL between 2000 and 2019 in Finland and aimed to clarify the incidence of late-onset cardiopulmonary morbidity compared to matched controls. Patient data were collected from four nationwide Finnish healthcare registries. We reported a higher occurrence of coronary artery disease in patients aged < 50 years at diagnosis than in controls (RR 3.80 (2.16-6.74), p < 0001). Additionally, a higher incidence of both heart failure (RR 1.68 (1.28-2.21), p < 0.001) and valvular heart disease (RR 1.80 (1.17-2.78), p = 0.006) was detected in patients aged ≥ 50 years at diagnosis than in the controls. Remarkably, in the < 50 years age group, the incidences of pneumonia (RR 4.89 (3.58-6.71), p < 0.001) and pulmonary embolism (RR 7.78 (2.75-21.95), p < 0.001) were higher than those in the control group. In conclusion, with the current treatment modalities, late cardiopulmonary morbidity in long-term survivors remains a great challenge. A strategy for primary prevention and early detection of late toxicity remains crucial and a critical evaluation of current treatment practices is warranted.
PMID:
42894041
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 16
- Comments 0